Researchers discover a potential biomarker for episodic migraine in women.
Researchers report amplified EEG can produce diagnostic results of brain waves associated with migraine and epilepsy non-invasively.
Six months following COVID-19 infection, two-thirds of patients still experienced neurological symptoms including headaches, memory impairment, and decreased concentration that impacted their quality of life.
The loss of TRESK significantly increases the risk of developing headaches and may be implicated in migraines.
Exposing migraine sufferers to a narrow band of green light may help to reduce the severity of the headache, a new study reports.
Fatigue and headaches top the list of common lingering symptoms four months after COVID infection, with muscle aches, changes in sense of taste and smell, cough, and congestion following close behind.
Researchers report ketamine may help to relieve pain symptoms associated with migraine in patients for whom other treatments have failed.
Many people who suffer migraines are often diagnosed with other conditions. For those with a clinical diagnosis, many are unaware of treatment options available for pain and to slow the frequency of attacks.
Neurological and psychological symptoms associated with COVID-19 infection, such as fatigue and depression, are more common in those with mild coronavirus infection than previously believed.
A new study reports a novel drug designed to treat migraine was associated with fewer headache hours for sufferers within 3 to 7 days following their first injection.
A new study reports some genes associated with vascular problems are also associated with migraines.
Researchers have identified a positive association between persistent lower back pain and headache disorders. The study reveals those with persistent back pain or persistent headache disorders are twice as likely to suffer from both disorders at the same time.
